{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"18.500","floor":"17.000"},"ipodate":{"start":"2020-06-16 00:00:00","end":"2020-06-19 00:00:00"},"minimumcapital":"3737.29","subscribed":"608.56","marketcap":"111.00億","H_marketcap":"--","pe":"250.68","codesrate":"8.80","link":"https://staticpdf.iqdii.com/stockdata/notice/06078/2020/2020061600026_c.pdf","ipopricing":"18.500","resultdate":"2020-06-26 00:00:00","enddate":"2020-06-19 00:00:00","listeddate":"2020-06-29 00:00:00","issuenumber":"12000.00萬","issuenumberhK":"6000.00萬","issuenumberother":"6000.00萬","grayprice":"23.50","sponsors":"摩根士丹利亞洲有限公司,海通國際資本有限公司","raisemoney":"207220.00萬","use":"1、約60%（或1,243.3百萬港元）將用于單縣海吉亞醫院、重慶海吉亞醫院及成武海吉亞醫院（均屬我們的自有營利性醫院）的升級，并在聊城、德州、蘇州及龍巖市設立新醫院；\n2、約30%（或621.7百萬港元）將用于合適機遇到來時，在人口龐大、對腫瘤醫療服務需求相對較高的新市場中收購醫院；\n3、約5%（或103.6百萬港元）將用于升級信息技術系統；\n4、約5%（或103.6百萬港元）將用于營運資金及其他一般企業用途。","shares":200,"leadagent":"摩根士丹利亞洲有限公司,海通國際證券有限公司,華泰金融控股(香港)有限公司","bookrunners":"摩根士丹利亞洲有限公司,海通國際證券有限公司,華泰金融控股(香港)有限公司","coordinator":"摩根士丹利亞洲有限公司,海通國際證券有限公司,華泰金融控股(香港)有限公司","firstDayOpen":"22.80","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E06078","name":"海吉亞醫療","fullname":"海吉亞醫療控股有限公司"},"institutioninfo":{"principaloffice":"中國上海市靜安區梅園路228號企業廣場702-707室","registrars":"卓佳證券登記有限公司","registrarstel":"(852) 2980 1333","chairman":"方敏","secretary":"任愛,劉國賢","telephone":"","substantialshareholders":"Century River(18.58%),Amber Tree(13.8%),Red Palm(13.8%),Fountain Grass(13.79%),Harmony Healthcare(6.2%)","principalactivities":"公司是中國最大的腫瘤醫療集團。","website":"http://www.hygeia-group.com.cn"},"managerinfo":[{"managername":"方敏","post":"主席兼非執行董事","rankno":1},{"managername":"程歡歡","post":"首席執行官兼執行董事","rankno":2},{"managername":"任愛","post":"執行董事","rankno":3}],"investorinfo":[{"institutionname":"Hillhouse Funds","shareholding":"20,945,600.0","percentage":17.45,"ReleaseDate":"2020-12-29 00:00:00","relatedparty":"Hillhouse Capital","subsidiary":["Gaoling Fund, L.P.","Hillhouse Funds","Gaoling Yali Fund, L.P.","HHJH Holdings Limited"],"InverstorType":"基金"},{"institutionname":"OrbiMed Funds","shareholding":"8,378,200.0","percentage":6.98,"ReleaseDate":"2020-12-29 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"Tiger Pacific Master Fund LP","shareholding":"6,702,600.0","percentage":5.59,"ReleaseDate":"2020-12-29 00:00:00","relatedparty":"Tiger Pacific Capital LP","subsidiary":["Tiger Pacific Master Fund LP"],"InverstorType":"基金"},{"institutionname":"南方基金管理股份有限公司","shareholding":"6,283,600.0","percentage":5.24,"ReleaseDate":"2020-12-29 00:00:00","relatedparty":"華泰證券股份有限公司","subsidiary":["華泰金融控股(香港)有限公司","南方基金管理股份有限公司"],"InverstorType":"公司"}],"TotalShareholdingPercentage":49.93},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":11}